Anthony Mancini will help Genmab take its next steps

Last year, Anthony Mancini was hired by Genmab. Today, he plays a key role in a new chapter at the company, as Genmab begins to market and sell its own products within cancer treatment for the first time.

Photo: Genmab

Few firms have been progressing at the same speed as Genmab has the past few years.

The Danish biotech company, which is specialized in cancer treatment, has seen both its revenue and share price skyrocket year after year. Historically, the growth has been due to Darzalex, which is marketed by Johnson & Johnson, but today, Genmab has five drugs contributing to its revenue.

Read the whole article

Get 14 days free access.
No credit card required.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

"Real world" patient data documents the long-term effects of ALK vaccines

In the largest study ever of its kind, patient data from the "real world" documents the long-term effects of up to nine years of ALK vaccines. Up until now, it has not been possible to demonstrate these in ordinary clinical studies where the follow-up period is shorter, and the new knowledge could be a turning point in ALK's dialog about prices and subsidies with authorities and payers. 

Further reading

Related articles

Latest news

See all jobs